Fecal microbiota transplant FMT , also known as a stool transplant , [ 2 ] is the process of transferring fecal bacteria and other microbes from a healthy individual into another individual.
Side effects may include a risk of infections , therefore the donor should be screened for pathogens. A study found that fecal microbiota transplant was an effective and simple procedure that was more cost-effective than continued antibiotic administration and reduced the incidence of antibiotic resistance.
Once considered to be a "last resort therapy" by some medical professionals, due to its unusual nature and invasiveness compared with antibiotics, perceived potential risk of infection transmission, and lack of Medicare coverage for donor stool, position statements by specialists in infectious diseases and other societies [ 14 ] have been moving toward acceptance of FMT as a standard therapy for relapsing CDI and also Medicare coverage in the United States.
It has been recommended that endoscopic FMT be elevated to first-line treatment for people with deterioration and severe relapsing C. In November , faecal microbiota transplant Biomictra was approved for medical use in Australia, [ 1 ] [ 18 ] and fecal microbiota, live Rebyota was approved for medical use in the United States.
Fecal microbiota spores, live Vowst was approved for medical use in the United States in April In May , Australian professor Thomas Borody treated the first ulcerative colitis patient using FMT, which led to longstanding symptom resolution.
